prof. dr. P.W.B. Derksen

prof. dr. P.W.B. Derksen

Full Professor
prof. dr. P.W.B. Derksen
  • Department of Pathology

Research Programs




Patrick Derksen (1970) obtained his PhD at the department of Pathology, Academic Medical Center, Amsterdam, The Netherlands. Following his graduation in 2003, he moved to the Netherlands Cancer Institute to study the consequences inactivation of cell-cell adhesion in breast cancer development and progression. Here he developed two mouse models for human invasive lobular carcinoma (ILC), by conditional and mammary-specific knockout of E-cadherin and p53. In 2005 he was awarded an independent researcher grant from the Dutch organization for scientific research (NWO-VENI) in 2005. In 2007, he joined the Medical Oncology department as an independent researcher and head of the UMCU Mouse Cancer Clinic. He received a NWO-VIDI award in 2008. In 2010 his position was tenured as an Associate Professor at the Department of Pathology.

His group is aiming at combining expertise on adhesion molecules, cell signaling and clinically relevant mouse models to study the downstream effectors of the adherens junction complex that propel breast cancer development and progression.

Research in the Derksen laboratory is currently sponsored by grants from NWO, KWF, H2020, STW and Breast Cancer Now.

Side Activities

Chair European Lobular Breast Cancer Consortium (ELBCC)

Chair COST Action #19138 LOBSTERPOT

Scientific Advisory Board Member of the Lobular Breast Cancer Alliance (LBCA)

co-investigator POSEIDON-2-Lobular Clinical intervention trial

Fellowship and Awards

NWO-VENI 916.56.135. (2006)

AICR 07-585. (2007)

Pink Ribbon  Award (2008)

NWO-VIDI 016.096.318. (2009)

KWF-UU 2011-5230 (2011)

Stichting Vrienden UMC Utrecht (2011)

KWF UU 2013-5801 (2013)

KWF-UU 2014-7201 (2015)

Research Output (55)

R-spondin-3 promotes proliferation and invasion of breast cancer cells independently of Wnt signaling

Ter Steege Eline J, Doornbos Loes W, Haughton Peter D, van Diest Paul J, Hilkens John, Derksen Patrick W B, Bakker Elvira R M 1 Aug 2023, In: Cancer Letters. 568 , p. 1-10

TLN1 contains a cancer-associated cassette exon that alters talin-1 mechanosensitivity

Gallego-Paez Lina M, Edwards William J S, Chanduri Manasa, Guo Yanyu, Koorman Thijs, Lee Chieh-Yu, Grexa Nina, Derksen Patrick, Yan Jie, Schwartz Martin A, Mauer Jan, Goult Benjamin Thomas 1 May 2023, In: The Journal of cell biology. 222

SKOR1 mediates FER kinase-dependent invasive growth of breast cancer cells

Sluimer Lilian M., Bullock Esme, Rätze Max A.K., Enserink Lotte, Overbeeke Celine, Hornsveld Marten, Brunton Valerie G., Derksen Patrick W.B., Tavares Sandra Feb 2023, In: Journal of cell science. 136

LGR6-dependent conditional inactivation of E-cadherin and p53 leads to invasive skin and mammary carcinomas in mice

Ter Steege Eline J, Sijnesael Thijmen, Enserink Lotte, Klarenbeek Sjoerd, Haakma Wisse E, Bakker Elvira R M, Derksen Patrick W B Jan 2023, In: Neoplasia. 35

Canonical Kaiso target genes define a functional signature that associates with breast cancer survival and the invasive lobular carcinoma histological type

Sijnesael Thijmen, Richard François, Rätze Max Ak, Koorman Thijs, Bassey-Archibong Blessing, Rohof Christa, Daniel Juliet, Desmedt Christine, Derksen Patrick Wb 2023, In: Journal of Pathology. 261 , p. 477-489 13 p.

The laminin-keratin link shields the nucleus from mechanical deformation and signalling

Kechagia Zanetta, Sáez Pablo, Gómez-González Manuel, Canales Brenda, Viswanadha Srivatsava, Zamarbide Martín, Andreu Ion, Koorman Thijs, Beedle Amy E M, Elosegui-Artola Alberto, Derksen Patrick W B, Trepat Xavier, Arroyo Marino, Roca-Cusachs Pere 2023, In: Nature materials. 22 , p. 1409-1420 12 p.

R-spondin-3 is an oncogenic driver of poorly differentiated invasive breast cancer

Ter Steege Eline J, Boer Mandy, Timmer Nikki C, Ammerlaan Carola Me, Song Ji-Ying, Derksen Patrick Wb, Hilkens John, Bakker Elvira Rm Nov 2022, In: Journal of Pathology. 258 , p. 289-299 11 p.

Small molecules to regulate the GH/IGF1 axis by inhibiting the growth hormone receptor synthesis

van der Velden Lieke M, Maas Peter, van Amersfoort Miranda, Timmermans-Sprang Elpetra P M, Mensinga Anneloes, van der Vaart Elisabeth, Malergue Fabrice, Viëtor Henk, Derksen Patrick W B, Klumperman Judith, van Agthoven Andreas, Egan David A, Mol Jan A, Strous Ger J 28 Jul 2022, In: Frontiers in Endocrinology. 13

Correction:Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer

Rätze Max A K, Koorman Thijs, Sijnesael Thijmen, Bassey-Archibong Blessing, van de Ven Robert, Enserink Lotte, Visser Daan, Jaksani Sridevi, Viciano Ignacio, Bakker Elvira R M, Richard François, Tutt Andrew, O'Leary Lynda, Fitzpatrick Amanda, Roca-Cusachs Pere, van Diest Paul J, Desmedt Christine, Daniel Juliet M, Isacke Clare M, Derksen Patrick W B 24 May 2022, In: Oncogene. 41 , p. 3507-3509 3 p.

Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer

Van Baelen K, Geukens T, Maetens M, Tjan-Heijnen V, Lord C J, Linn S, Bidard F-C, Richard F, Yang W W, Steele R E, Pettitt S J, Van Ongeval C, De Schepper M, Isnaldi E, Nevelsteen I, Smeets A, Punie K, Voorwerk L, Wildiers H, Floris G, Vincent-Salomon A, Derksen P W B, Neven P, Senkus E, Sawyer E, Kok M, Desmedt C 20 May 2022, In: Annals of oncology : official journal of the European Society for Medical Oncology. 33 , p. 769-785 17 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not